09:14 AMAllergan (AGN): Q2 EPS of $0.75 beats by $0.08. Revenue of $1.13B (-3.5%) in-line. Shares +0.8% premarket. Sees Q3 EPS of $0.67-0.69 vs. $0.72. (PR)
Comment!
09:49 AM
Sanofi-Aventis (SNY +1.6%) may be on the prowl for a mega pharma deal. Obvious targets include Bristol-Myers (BMY) and Amgen (AMGN), but smaller fry like Allergan (AGN) and Biogen Idec (BIIB) would be easier for SNY to digest without impairing its investment-grade credit rating.
Comment!
Wednesday, May 27, 2009
09:58 AM
FDA tells Allergan (AGN -1%) it needs more info about Botox before approving it to treat post-stroke spasticity of the upper limbs, but doesn't ask for new trials. Analysts say the news - which could delay approval for 8-9 months - is disappointing, but doesn't hamper the long-term outlook.
Comment!
Friday, May 1, 2009
09:10 AMAllergan (AGN): Q1 EPS of $0.55 beats by $0.02. Revenue of $1.01B (-6.4%) in-line. Q2 and full-year guidance in-line. Shares -1.4% premarket. (PR)
Comment!
15:42 PMLove the Long Eyelashes. Who’s Your Doctor? Allergan (AGN) plans to introduce Latisse, the first FDA-approved drug for growing longer eyelashes, later this month. Will the not-so-rich and vain really shell out $120/month for eye candy?1 Comment
Wednesday, December 24, 2008
07:23 AM
At Mattel (MAT), plans for a new, edgier Barbie. MAT hopes Barbie 2.0 will appeal to the tweens, and goose sales which have been flat for five of the past seven years. At 49, maybe they should consider Botox (AGN).
Comment!